Company intelligence / Profile preview

Bantry Therapeutics

Houston, TX, United States

Ownership: Private
Development stage: Other

Overview

Bantry Therapeutics is a Houston-based biotechnology company dedicated to developing transformative therapies for fibrotic diseases. The company's research focuses on the Hippo signaling pathway, specifically targeting the YAP/TAZ/TEAD transcriptional complex which acts as a master regulator of fibrosis. By utilizing potent small molecule inhibitors, Bantry aims to halt and potentially reverse the progression of fibrosis in organs such as the lungs, liver, and kidneys. Their lead asset, BTX-001, is currently undergoing preclinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and other high-need fibrotic conditions.

Therapeutic areas: NephrologyRheumatologyPulmonologyGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Bantry Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bantry Therapeutics.

Explore the full profile